Trident Mediquip Limited completes private placement; Trident Lifeline Ltd stake settles at 58.84%
Trident Lifeline Limited announced that its subsidiary, Trident Mediquip Limited (TML), successfully completed a private placement of equity shares to other shareholders. Following this transaction, Trident Lifeline Limited's shareholding in the medical device company stands at 58.84%.The private placement involved TML, which operates within the Medical Device Industry. Trident Mediquip Limited is incorporated under the Companies Act, 2013, and has a paid-up share capital of Rs. 9,97,00,000/- divided into 99,70,000 Equity Shares of Rs.10/- each, against an authorized share capital of Rs. 10,00,00,000/-.
The transaction is recognized as a related party matter, given that TML is a subsidiary of Trident Lifeline Limited. The company confirmed that the acquisition process was undertaken on an arm's length basis.
Operational and Financial Overview of TML
TML has been operating in the medical device sector since its incorporation on October 19, 2019. The company demonstrated consistent growth over the last three financial years, with turnover increasing progressively.Key operational details for Trident Mediquip Limited are presented below:
| Metric | Details |
|---|---|
| Industry | Medical Device Industry |
| Incorporation Date | October 19, 2019 |
| Pre-holding of TLL in TML | 59.17% |
| Post-holding of TLL in TML | 58.84% |
TML's turnover for the past three financial years is detailed as follows:
| Financial Year | Turnover (Cr) |
|---|---|
| 2023-24 | 20.58 Cr |
| 2024-25 | 21.29 Cr |
| 2025-26 | 27.31 Cr |
Stock Price Movement
At the close of trade today, Trident Lifeline Ltd shares settled at ₹246.15, edging higher after a 1.30% gain. Throughout the day, the stock ranged between an intraday low of ₹245.60 and a high mark of ₹248.10.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.